Related Experiment Video

Updated: May 10, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma

Scott S Tykodi1

  • 1Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA 98109-1023, USA. stykodi@fhcrc.org

Immunotherapy
|June 4, 2013
PubMed

Insights

Blocking immune checkpoints shows promise for advanced clear cell renal cell carcinoma immunotherapy by overcoming tumor resistance to T cell therapies. Further trials and combination therapies are being explored.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapy

Background:

  • Adaptive immune responses impact cancer progression and treatment outcomes.
  • Tumor resistance mechanisms often limit the effectiveness of T cell-based cancer therapies.
  • Immune checkpoints (inhibitory coreceptors on T cells) regulate adaptive immune responses.

Purpose of the Study:

  • To review early-phase clinical trial results for blocking antibodies targeting immune checkpoints.
  • To evaluate the potential of these therapies in advanced clear cell renal cell carcinoma.
  • To discuss future clinical testing and combination strategies.

Main Methods:

  • Overview of early-phase clinical trial data.
  • Analysis of immune checkpoint inhibitor efficacy.
  • Review of therapeutic outcomes in clear cell renal cell carcinoma patients.

Main Results:

  • Blocking antibodies targeting inhibitory coreceptors show significant promise.
  • These approaches are particularly relevant for advanced clear cell renal cell carcinoma.
  • Immune checkpoint blockade represents a viable cancer immunotherapy strategy.

Conclusions:

  • Immune checkpoint inhibitors are a promising immunotherapy for advanced clear cell renal cell carcinoma.
  • Further clinical trials and novel therapy combinations are warranted.
  • Overcoming tumor resistance is key to enhancing T cell-mediated cancer therapies.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers12:22

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...